Intrinsic value of ChromaDex - CDXC

Previous Close

$3.39

  Intrinsic Value

$0.24

stock screener

  Rating & Target

str. sell

-93%

Previous close

$3.39

 
Intrinsic value

$0.24

 
Up/down potential

-93%

 
Rating

str. sell

We calculate the intrinsic value of CDXC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  34
  52
  78
  114
  160
  221
  296
  389
  500
  632
  785
  959
  1,156
  1,376
  1,618
  1,882
  2,168
  2,475
  2,803
  3,151
  3,519
  3,907
  4,314
  4,740
  5,185
  5,649
  6,132
  6,635
  7,158
  7,701
Variable operating expenses, $m
  39
  60
  89
  129
  182
  251
  336
  442
  568
  717
  891
  1,089
  1,313
  1,562
  1,836
  2,136
  2,461
  2,809
  3,182
  3,577
  3,995
  4,435
  4,897
  5,381
  5,886
  6,413
  6,961
  7,532
  8,126
  8,742
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  39
  60
  89
  129
  182
  251
  336
  442
  568
  717
  891
  1,089
  1,313
  1,562
  1,836
  2,136
  2,461
  2,809
  3,182
  3,577
  3,995
  4,435
  4,897
  5,381
  5,886
  6,413
  6,961
  7,532
  8,126
  8,742
Operating income, $m
  -5
  -7
  -11
  -16
  -22
  -30
  -40
  -53
  -68
  -86
  -106
  -130
  -156
  -186
  -219
  -254
  -293
  -335
  -379
  -426
  -476
  -528
  -583
  -641
  -701
  -764
  -829
  -897
  -968
  -1,041
EBITDA, $m
  -4
  -6
  -8
  -12
  -17
  -24
  -32
  -42
  -54
  -68
  -85
  -104
  -125
  -149
  -175
  -203
  -234
  -267
  -303
  -340
  -380
  -422
  -466
  -512
  -560
  -610
  -662
  -717
  -773
  -832
Interest expense (income), $m
  0
  0
  2
  4
  7
  11
  16
  23
  32
  42
  55
  70
  88
  108
  130
  155
  183
  213
  246
  281
  319
  358
  401
  445
  492
  540
  591
  644
  700
  757
  817
Earnings before tax, $m
  -5
  -9
  -14
  -22
  -33
  -46
  -63
  -84
  -110
  -141
  -176
  -217
  -264
  -316
  -374
  -437
  -506
  -580
  -660
  -745
  -834
  -929
  -1,028
  -1,133
  -1,241
  -1,355
  -1,474
  -1,597
  -1,725
  -1,858
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -5
  -9
  -14
  -22
  -33
  -46
  -63
  -84
  -110
  -141
  -176
  -217
  -264
  -316
  -374
  -437
  -506
  -580
  -660
  -745
  -834
  -929
  -1,028
  -1,133
  -1,241
  -1,355
  -1,474
  -1,597
  -1,725
  -1,858

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  40
  62
  93
  135
  191
  262
  352
  462
  594
  750
  932
  1,139
  1,373
  1,634
  1,921
  2,235
  2,574
  2,939
  3,329
  3,742
  4,180
  4,640
  5,124
  5,630
  6,158
  6,709
  7,283
  7,880
  8,501
  9,146
Adjusted assets (=assets-cash), $m
  40
  62
  93
  135
  191
  262
  352
  462
  594
  750
  932
  1,139
  1,373
  1,634
  1,921
  2,235
  2,574
  2,939
  3,329
  3,742
  4,180
  4,640
  5,124
  5,630
  6,158
  6,709
  7,283
  7,880
  8,501
  9,146
Revenue / Adjusted assets
  0.850
  0.839
  0.839
  0.844
  0.838
  0.844
  0.841
  0.842
  0.842
  0.843
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
  0.842
Average production assets, $m
  5
  7
  11
  15
  22
  30
  40
  53
  68
  86
  107
  130
  157
  187
  220
  256
  295
  337
  381
  429
  479
  531
  587
  645
  705
  768
  834
  902
  973
  1,047
Working capital, $m
  6
  9
  14
  20
  28
  38
  51
  67
  87
  109
  136
  166
  200
  238
  280
  326
  375
  428
  485
  545
  609
  676
  746
  820
  897
  977
  1,061
  1,148
  1,238
  1,332
Total debt, $m
  6
  13
  24
  39
  58
  83
  114
  152
  199
  253
  316
  388
  470
  560
  660
  770
  888
  1,015
  1,150
  1,294
  1,446
  1,607
  1,775
  1,951
  2,135
  2,327
  2,526
  2,734
  2,950
  3,175
Total liabilities, $m
  14
  22
  32
  47
  66
  91
  122
  161
  207
  261
  324
  396
  478
  569
  669
  778
  896
  1,023
  1,158
  1,302
  1,455
  1,615
  1,783
  1,959
  2,143
  2,335
  2,534
  2,742
  2,958
  3,183
Total equity, $m
  26
  41
  61
  88
  124
  171
  229
  301
  387
  489
  608
  743
  895
  1,065
  1,253
  1,457
  1,678
  1,916
  2,170
  2,440
  2,725
  3,026
  3,341
  3,671
  4,015
  4,374
  4,749
  5,138
  5,543
  5,963
Total liabilities and equity, $m
  40
  63
  93
  135
  190
  262
  351
  462
  594
  750
  932
  1,139
  1,373
  1,634
  1,922
  2,235
  2,574
  2,939
  3,328
  3,742
  4,180
  4,641
  5,124
  5,630
  6,158
  6,709
  7,283
  7,880
  8,501
  9,146
Debt-to-equity ratio
  0.220
  0.330
  0.400
  0.440
  0.470
  0.490
  0.500
  0.510
  0.510
  0.520
  0.520
  0.520
  0.520
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
  0.530
Adjusted equity ratio
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652
  0.652

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -5
  -9
  -14
  -22
  -33
  -46
  -63
  -84
  -110
  -141
  -176
  -217
  -264
  -316
  -374
  -437
  -506
  -580
  -660
  -745
  -834
  -929
  -1,028
  -1,133
  -1,241
  -1,355
  -1,474
  -1,597
  -1,725
  -1,858
Depreciation, amort., depletion, $m
  1
  2
  2
  3
  5
  6
  8
  11
  14
  17
  21
  26
  31
  37
  44
  51
  59
  67
  76
  86
  96
  106
  117
  129
  141
  154
  167
  180
  195
  209
Funds from operations, $m
  -4
  -7
  -12
  -19
  -28
  -40
  -55
  -74
  -96
  -123
  -155
  -191
  -232
  -279
  -330
  -386
  -447
  -513
  -584
  -659
  -739
  -823
  -911
  -1,004
  -1,100
  -1,201
  -1,307
  -1,416
  -1,530
  -1,649
Change in working capital, $m
  2
  3
  4
  6
  8
  10
  13
  16
  19
  23
  26
  30
  34
  38
  42
  46
  49
  53
  57
  60
  64
  67
  70
  74
  77
  80
  84
  87
  90
  94
Cash from operations, $m
  -6
  -10
  -17
  -25
  -36
  -50
  -68
  -90
  -116
  -146
  -181
  -221
  -267
  -317
  -372
  -432
  -497
  -566
  -641
  -719
  -802
  -890
  -981
  -1,077
  -1,177
  -1,282
  -1,390
  -1,503
  -1,621
  -1,743
Maintenance CAPEX, $m
  -1
  -1
  -1
  -2
  -3
  -4
  -6
  -8
  -11
  -14
  -17
  -21
  -26
  -31
  -37
  -44
  -51
  -59
  -67
  -76
  -86
  -96
  -106
  -117
  -129
  -141
  -154
  -167
  -180
  -195
New CAPEX, $m
  -2
  -3
  -4
  -5
  -6
  -8
  -10
  -13
  -15
  -18
  -21
  -24
  -27
  -30
  -33
  -36
  -39
  -42
  -45
  -47
  -50
  -53
  -55
  -58
  -61
  -63
  -66
  -68
  -71
  -74
Cash from investing activities, $m
  -3
  -4
  -5
  -7
  -9
  -12
  -16
  -21
  -26
  -32
  -38
  -45
  -53
  -61
  -70
  -80
  -90
  -101
  -112
  -123
  -136
  -149
  -161
  -175
  -190
  -204
  -220
  -235
  -251
  -269
Free cash flow, $m
  -8
  -14
  -22
  -32
  -46
  -63
  -84
  -110
  -141
  -178
  -219
  -266
  -319
  -378
  -442
  -512
  -587
  -667
  -752
  -843
  -938
  -1,038
  -1,143
  -1,253
  -1,367
  -1,486
  -1,610
  -1,739
  -1,872
  -2,012
Issuance/(repayment) of debt, $m
  5
  8
  11
  15
  19
  25
  31
  38
  46
  54
  63
  72
  81
  91
  100
  109
  118
  127
  136
  144
  152
  160
  168
  176
  184
  192
  200
  208
  216
  225
Issuance/(repurchase) of shares, $m
  15
  23
  35
  50
  69
  93
  122
  156
  196
  243
  294
  353
  416
  486
  561
  642
  728
  818
  914
  1,014
  1,120
  1,229
  1,343
  1,462
  1,586
  1,714
  1,848
  1,986
  2,130
  2,279
Cash from financing (excl. dividends), $m  
  20
  31
  46
  65
  88
  118
  153
  194
  242
  297
  357
  425
  497
  577
  661
  751
  846
  945
  1,050
  1,158
  1,272
  1,389
  1,511
  1,638
  1,770
  1,906
  2,048
  2,194
  2,346
  2,504
Total cash flow (excl. dividends), $m
  11
  17
  24
  32
  42
  55
  69
  84
  101
  119
  138
  158
  178
  199
  219
  239
  259
  278
  297
  316
  334
  351
  369
  386
  403
  420
  438
  455
  474
  492
Retained Cash Flow (-), $m
  -15
  -23
  -35
  -50
  -69
  -93
  -122
  -156
  -196
  -243
  -294
  -353
  -416
  -486
  -561
  -642
  -728
  -818
  -914
  -1,014
  -1,120
  -1,229
  -1,343
  -1,462
  -1,586
  -1,714
  -1,848
  -1,986
  -2,130
  -2,279
Prev. year cash balance distribution, $m
  38
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  35
  -6
  -11
  -17
  -26
  -38
  -53
  -72
  -95
  -123
  -156
  -194
  -238
  -287
  -342
  -403
  -469
  -540
  -617
  -699
  -786
  -878
  -975
  -1,077
  -1,183
  -1,294
  -1,410
  -1,531
  -1,656
  -1,787
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  33
  -6
  -9
  -14
  -20
  -28
  -36
  -45
  -55
  -65
  -74
  -83
  -90
  -96
  -100
  -102
  -102
  -99
  -95
  -89
  -81
  -73
  -64
  -55
  -46
  -38
  -30
  -24
  -18
  -13
Current shareholders' claim on cash, %
  79.1
  63.0
  50.6
  40.9
  33.4
  27.5
  22.8
  19.1
  16.0
  13.6
  11.6
  9.9
  8.5
  7.4
  6.4
  5.6
  4.9
  4.3
  3.8
  3.3
  2.9
  2.6
  2.3
  2.0
  1.8
  1.6
  1.4
  1.3
  1.1
  1.0

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

FINANCIAL RATIOS  of  ChromaDex (CDXC)

Valuation Ratios
P/E Ratio -42.4
Price to Sales 4.7
Price to Book 12.7
Price to Tangible Book
Price to Cash Flow -42.4
Price to Free Cash Flow -25.5
Growth Rates
Sales Growth Rate 22.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 100%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 10%
Total Debt to Equity 10%
Interest Coverage 0
Management Effectiveness
Return On Assets -15.4%
Ret/ On Assets - 3 Yr. Avg. -27.5%
Return On Total Capital -27.3%
Ret/ On T. Cap. - 3 Yr. Avg. -45.8%
Return On Equity -40%
Return On Equity - 3 Yr. Avg. -68.9%
Asset Turnover 1.4
Profitability Ratios
Gross Margin 44.4%
Gross Margin - 3 Yr. Avg. 38%
EBITDA Margin -11.1%
EBITDA Margin - 3 Yr. Avg. -19.4%
Operating Margin -7.4%
Oper. Margin - 3 Yr. Avg. -18.8%
Pre-Tax Margin -11.1%
Pre-Tax Margin - 3 Yr. Avg. -19.4%
Net Profit Margin -11.1%
Net Profit Margin - 3 Yr. Avg. -19.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CDXC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CDXC stock intrinsic value calculation we used $21.201482 million for the last fiscal year's total revenue generated by ChromaDex. The default revenue input number comes from 0001 income statement of ChromaDex. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CDXC stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CDXC is calculated based on our internal credit rating of ChromaDex, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of ChromaDex.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CDXC stock the variable cost ratio is equal to 114.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CDXC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 27.7% for ChromaDex.

Corporate tax rate of 27% is the nominal tax rate for ChromaDex. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CDXC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CDXC are equal to 13.6%.

Life of production assets of 4.7 years is the average useful life of capital assets used in ChromaDex operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CDXC is equal to 17.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $53.834 million for ChromaDex - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 55.055 million for ChromaDex is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of ChromaDex at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
A Agilent Techno 63.47 100.49  str.buy
LH Laboratory of 163.87 231.36  buy
TMO Thermo Fisher 235.08 199.97  hold
SNMX Senomyx 1.49 0.10  str.sell
GRA W.R. Grace 63.82 75.16  hold

COMPANY NEWS

▶ ChromaDex: 3Q Earnings Snapshot   [05:59PM  Associated Press]
▶ ChromaDex: 2Q Earnings Snapshot   [Aug-09-18 07:07PM  Associated Press]
▶ ChromaDex Corporations (NASDAQ:CDXC) Path To Profitability   [May-09-18 09:47AM  Simply Wall St.]
▶ ChromaDex reports 4Q loss   [Mar-08-18 04:40PM  Associated Press]
▶ ChromaDex Corporation Reports Preliminary 2017 Results   [Feb-12-18 06:30AM  GlobeNewswire]
▶ ChromaDex to Present at the 3rd Annual NAD+ Summit   [Jan-24-18 06:30AM  GlobeNewswire]
▶ ChromaDex to Present at the 10th Annual LD Micro Main Event   [Nov-29-17 06:30AM  GlobeNewswire]
▶ ChromaDex posts 3Q profit   [Nov-09-17 06:13PM  Associated Press]
▶ ETFs with exposure to Chromadex Corp. : November 8, 2017   [Nov-08-17 05:43PM  Capital Cube]
▶ ETFs with exposure to Chromadex Corp. : October 27, 2017   [Oct-27-17 10:48AM  Capital Cube]
▶ ChromaDex to Present at the 2017 BIO Investor Forum   [Oct-16-17 06:30AM  GlobeNewswire]
▶ ETFs with exposure to Chromadex Corp. : October 10, 2017   [Oct-10-17 11:08AM  Capital Cube]
▶ ChromaDex Appoints Kevin Farr as New CFO   [Oct-09-17 06:30AM  GlobeNewswire]
▶ LabCorp purchases analytical testing services business in $8.5 million deal   [Aug-23-17 02:50PM  American City Business Journals]
▶ ChromaDex reports 2Q loss   [Aug-10-17 10:05PM  Associated Press]
▶ ETFs with exposure to Chromadex Corp. : August 1, 2017   [Aug-01-17 04:22PM  Capital Cube]
▶ ETFs with exposure to Chromadex Corp. : July 13, 2017   [Jul-13-17 03:44PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.